Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Kota Ishioka"'
Autor:
Shinji Sasada, Morio Nakamura, Takashi Shimada, Tomohide Adachi, Kota Ishioka, Saeko Takahashi, Tomoyo Oguri
Publikováno v:
Internal Medicine
Background Homeless persons are those who carry out their activities of daily living in city parks and other facilities. Little is known about homeless patients with lung cancer in Japan. Therefore, we characterized the clinical features and outcomes
Autor:
Morio Nakamura, Reishi Seki, Satoko Shimizu, Kota Ishioka, Tomoyo Oguri, Shinji Sasada, Yoshifumi Kimura, Risa Shigematsu, Shigemichi Hirose, Koichi Oki, Saeko Takahashi, Yumi Tsuchiya
Publikováno v:
Journal of Investigative Medicine High Impact Case Reports, Vol 9 (2021)
Journal of Investigative Medicine High Impact Case Reports
Journal of Investigative Medicine High Impact Case Reports
A 76-year-old man was admitted to our hospital with Guillain-Barré syndrome (GBS), presenting with facial palsy, dysarthria, and dysphagia as Grade 3 immune-related adverse events (irAEs) due to pembrolizumab administration for Stage IV lung adenoca
Autor:
Yuki Aramaki-Sumii, Hisako Kunieda, Yoshifumi Kimura, Kota Ishioka, Shinji Sasada, Tomoyo Oguri, Reishi Seki, Morio Nakamura, Shigemichi Hirose, Saeko Takahashi, Yumi Tsuchiya
Publikováno v:
Journal of Investigative Medicine High Impact Case Reports
Journal of Investigative Medicine High Impact Case Reports, Vol 9 (2021)
Journal of Investigative Medicine High Impact Case Reports, Vol 9 (2021)
Intravascular large B-cell lymphoma (IVLBCL) is a rare form of diffuse LBCL. The patient was a 71-year-old female admitted to our hospital with hypoxia. On admission, chest computed tomography revealed a ground-glass opacity. Interstitial pneumonia a
Autor:
Hiroyuki Yasuda, Daisuke Arai, Takashi Kohno, Junko Hamamoto, Shingo Matsumoto, Mitsugu Araki, Ho Namkoong, Kota Ishioka, Koichi Goto, Yuichiro Hayashi, Ryo Kanada, Susumu Kobayashi, Katsuya Tsuchihara, Morio Nakamura, Shinnosuke Ikemura, Keigo Kobayashi, Ichiro Nakachi, Tadashi Manabe, Ichiro Kawada, Kiyotaka Yoh, Keita Masuzawa, Biao Ma, Kenzo Soejima, Katsuhiko Naoki, Mayumi Kamada, Sachiyo Mimaki, Yasushi Okuno, Fumie Ono
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America. 116(20):10025-10030
Next generation sequencing (NGS)-based tumor profiling identified an overwhelming number of uncharacterized somatic mutations, also known as variants of unknown significance (VUS). The therapeutic significance of EGFR mutations outside mutational hot
Autor:
Yumi Tsuchiya, Morio Nakamura, Ryohei Katayama, Shinji Sasada, Saori Murata, Tomoyo Oguri, Saeko Takahashi, Reishi Seki, Kota Ishioka, Shigemichi Hirose, Sachiko Seki
Publikováno v:
Respiratory Medicine Case Reports, Vol 33, Iss, Pp 101405-(2021)
Respiratory Medicine Case Reports
Respiratory Medicine Case Reports
A 66-year old man with non-smoking history was diagnosed with pulmonary pleomorphic carcinoma of the right lower lobe. The carcinoma metastasized to the brain, lungs, pleura, and mediastinal lymph nodes. It was positive for epidermal growth factor re
Autor:
Koichi Fukunaga, Keiko Ohgino, Shigenari Nukaga, Daisuke Arai, Kenzo Soejima, Hiroyuki Yasuda, Junko Hamamoto, Katsuhiko Naoki, Tetsuo Tani, Aoi Kuroda, Keita Masuzawa, Shinnosuke Ikemura, Kota Ishioka, Hideki Terai, Ichiro Kawada
Publikováno v:
Cancer Science
ABT‐263 (Navitoclax) is a BH3‐mimetic drugs targeting anti‐apoptotic B‐cell lymphoma‐2 (BCL‐2) family proteins, including BCL‐2, BCL‐xL, and BCL‐w, thereby inducing apoptosis. In small‐cell lung cancer (SCLC) cells, the response t
Autor:
Koichi Sayama, Kota Ishioka, Ichiro Kawada, Keiko Ohgino, Daisuke Arai, Naoki Miyao, Shigenari Nukaga, Morio Nakamura, Fumio Sakamaki, Daisuke Fujisawa, Mari Takeuchi, Takashi Sato, Takeshi Terashima, Katsunori Masaki, Yohei Funatsu, Yoshitaka Oyamada, Ichiro Nakachi, Kota Hikima, Keigo Kobayashi, Tomoko Betsuyaku, Fumitake Saito, Hiroyuki Yasuda, Katsuhiko Naoki, Takashi Inoue, Kenzo Soejima
Publikováno v:
The Oncologist. 23:1218-1229
Background Prognostic understanding in advanced cancer patients and their caregivers may have an impact on the delivery of effective care. The aims of this study were to explore prognostic understanding at diagnosis in both patients with advanced lun
Autor:
Tomoko Betsuyaku, Kota Ishioka, Yuichiro Hayashi, Ichiro Kawada, Kenzo Soejima, Masayoshi Miyawaki, Toshiyuki Hirano, Hiroyuki Yasuda, Shigenari Nukaga, Keiko Ohgino, Daisuke Arai, Junko Hamamoto, Tetsuo Tani, Katsuhiko Naoki
Publikováno v:
Molecular Cancer Research. 15:106-114
Activation of the EGFR pathway is one of the mechanisms inducing acquired resistance to anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI) such as crizotinib and alectinib. Ceritinib is a highly selective ALK inhibitor and shows promis
Autor:
Hiroyuki Yasuda, Ryosuke Satomi, Takashi Sato, Katsuhiko Naoki, Shinnosuke Ikemura, Keiko Ohgino, Sohei Nakayama, Daisuke Arai, Tetsuo Tani, Kenzo Soejima, Kota Ishioka, Hideki Terai, Satoshi Yoda
Publikováno v:
Cancer chemotherapy and pharmacology. 84(5)
No consensus has been reached regarding the treatment order and timing of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and cytotoxic chemotherapy administration for EGFR mutation-positive non-small cell lung cancer (NSCLC) pa
Autor:
Aoi Kuroda, Tomoko Betsuyaku, Kota Ishioka, Keiko Ohgino, Katsuhiko Naoki, Daisuke Arai, Hiroyuki Yasuda, Ichiro Kawada, Kenzo Soejima, Junko Hamamoto, Tetsuo Tani, Yuichiro Hayashi, Masayoshi Miyawaki
Publikováno v:
Molecular Cancer Therapeutics. 15:162-171
Alectinib is a highly selective ALK inhibitor and shows promising efficacy in non–small cell lung cancers (NSCLC) harboring the EML4-ALK gene rearrangement. The precise mechanism of acquired resistance to alectinib is not well defined. The purpose